Welcome to our dedicated page for Cidara Theraptcs news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Theraptcs stock.
Cidara Therapeutics (CDTX) delivers innovative solutions for serious infectious diseases through its Cloudbreak® platform, which engineers targeted immunotherapies and anti-infectives. This page provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements about CDTX's pipeline candidates, antiviral DFC advancements, and partnership agreements. Our curated collection includes press releases on trial results, FDA interactions, and research collaborations – all critical for evaluating the company's progress in addressing unmet medical needs.
Key updates cover three focus areas: clinical trial phases for antifungal/antiviral therapies, technology licensing deals involving the Cloudbreak® platform, and financial developments impacting R&D priorities. Bookmark this resource to monitor how CDTX's dual approach of direct pathogen targeting and immune system engagement evolves across influenza, oncology, and fungal infection programs.
Cidara Therapeutics (CDTX) reported its financial results for Q4 and FY 2020, revealing revenues of $3.7 million and $12.1 million, down from $1.8 million and $20.9 million in 2019. The company faced a net loss of $21.6 million in Q4 and $72.1 million for the year, increasing from $14.0 million and $41.1 million in 2019. Cash reserves decreased to $42.9 million. Cidara emphasized its clinical progress with rezafungin and plans to report data from the ReSTORE trial by end of 2021. The company also announced new Board appointments to strengthen its management team.
Cidara Therapeutics (Nasdaq: CDTX) announced new analyses from the completed Phase 2 STRIVE trial for rezafungin, a once-weekly echinocandin, demonstrating safety and efficacy in treating candidemia and invasive candidiasis among high-risk immunocompromised patients. The overall response rate was 75% in patients treated with rezafungin compared to 66.7% for the standard of care. Additionally, rezafungin's efficacy remained unaffected by renal impairment. Cidara is advancing rezafungin through Phase 3 trials for candidemia and invasive fungal disease prevention.
Cidara Therapeutics (Nasdaq: CDTX) announced its participation in the 21st International Immunocompromised Host Society Symposium, occurring virtually from Feb. 17-19, 2021. The company will present significant findings on rezafungin, its novel once-weekly echinocandin currently in Phase 3 trials for treating serious fungal infections. Key presentations include an oral overview by Dr. Taylor Sandison and three poster presentations focused on rezafungin's efficacy. Additionally, Cidara will showcase preclinical data on its antiviral conjugate candidate, CD377, targeting influenza.
Cidara Therapeutics (Nasdaq: CDTX) announced the addition of Bonnie Bassler, Ph.D., and Carin Canale-Theakston to its board of directors. Dr. Bassler brings extensive molecular biology expertise and experience from various biotech boards, while Canale-Theakston boasts over 25 years in life sciences communications. Their appointments aim to bolster the company's focus on advancing its antifungal candidate, rezafungin, which is currently in Phase 3 trials, and its antiviral conjugate programs targeting influenza.
Cidara Therapeutics (Nasdaq: CDTX) has granted a stock option for 115,000 shares to a new employee under its 2020 Inducement Incentive Plan, effective December 31, 2020. The exercise price is $2.00 per share, equal to the closing price on the grant date. The option vests over four years, with 25% vesting after one year and the remainder in monthly installments. This award complies with Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee's hiring. Cidara focuses on long-acting therapeutics for serious fungal and viral infections, including its lead candidate, rezafungin.
Cidara Therapeutics, Inc. (Nasdaq: CDTX) has appointed Christopher Kurtz as executive vice president of technical operations to advance its antifungal and antiviral programs. With over 26 years of experience, Kurtz's expertise in manufacturing and supply chain management is expected to drive the company's ongoing Phase 3 trials of rezafungin, aimed at treating serious fungal infections. The company also seeks to leverage its Cloudbreak platform for developing long-acting antiviral conjugates against various viruses. The leadership change is viewed as a pivotal step for Cidara's growth and product development.
Cidara Therapeutics (Nasdaq: CDTX) announced its participation in the 7th European Scientific Working Group on Influenza (ESWI) Conference, scheduled for Dec. 6-9, 2020. Highlights include a keynote lecture on the innovative Cloudbreak antiviral platform aimed at universal influenza protection, delivered by Les Tari, Ph.D., on Dec. 7. Additionally, presentations will feature preclinical data on the antiviral conjugate CD377, focusing on its efficacy against various influenza strains, including HPAI and Oseltamivir-resistant isolates. These findings promise advancements in preventing and treating influenza.
Cidara Therapeutics (Nasdaq: CDTX) announced plans to present three posters at the ESICM LIVES 2020 virtual conference from December 6-9, 2020. The presentations will focus on findings from the Phase 2 STRIVE trial of rezafungin for treating candidemia and invasive candidiasis. Key analyses include ICU status, geographic enrollment, and body mass index outcomes compared to caspofungin. Rezafungin is currently undergoing pivotal Phase 3 trials. For further details, copies of the posters will be available on Cidara's website.
Cidara Therapeutics (Nasdaq: CDTX) announced that its CEO, Jeffrey Stein, Ph.D., will participate in two upcoming virtual conferences. The first is the Stifel 2020 Virtual Healthcare Conference, scheduled for November 17, 2020, at 2:00 PM ET. The second event is the 3rd Annual Evercore ISI HealthCONx Conference on December 2, 2020, at 11:20 AM ET, featuring a panel discussion focused on fungal needs. Cidara specializes in developing long-acting therapeutics for fungal and viral infections, including its lead antifungal candidate, rezafungin.